| Literature DB >> 27119072 |
Fabíola Maria Marques do Couto1, Silene Carneiro do Nascimento2, Silvio Francisco Pereira Júnior1, Vanessa Karina Alves da Silva1, André Ferraz Goiana Leal1, Rejane Pereira Neves1.
Abstract
This work aimed to evaluate the antifungal activity of piroctone olamine in the treatment of intra-abdominal candidiasis in an experimental model using Swiss mice. The mice (n = 6) were infected by intraperitoneal injection of 0.2 ml of C. albicans (10(7)cells/ml in saline). The animals were observed daily for clinical signs and mortality for 14 days. The treatment with piroctone olamine (0.5 mg/kg) was performed 72 h after infection by intraperitoneal administration. For comparison, a group of animals (n = 6) was treated with amphotericin B (0.5 mg/kg). The mycological diagnosis was made by collecting the liver, spleen and kidneys. Data regarding the fungal growth and mortality were analyzed statistically by Student's t test and analysis of variance (ANOVA), with level of significance set at P < 0.05. The difference in fungal growth scoring between the control group and the treatment groups (piroctone olamine and amphotericin B) was statistically significant (P < 0.05). The difference in fungal growth scoring between the treatment groups (piroctone olamine and amphotericin B) was not statistically significant (P < 0.05).Entities:
Keywords: Activity antifungal; Intra-abdominal candidiasis; Piroctone olamine
Year: 2016 PMID: 27119072 PMCID: PMC4833761 DOI: 10.1186/s40064-016-2130-8
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Evaluation of minimum inhibitory concentration (MIC) of fluconazole (FLZ), amphotericin B (AMB) and piroctone olamine (PO) against Candida species as agents of fungemia
| Species | Number (%) | Drugs | MIC range (μg/ml)/average |
|---|---|---|---|
|
| 10 (23.26 %) | AMB | 0.03–0.5 (0.01) |
| FLZ | 0.5–16 (4.6) | ||
| PO | 0.125–0.25 (0.19) | ||
|
| 13 (30.23 %) | AMB | 0.03–0.5 (0.10) |
| FLZ | 0.5–64 (6.5) | ||
| PO | 0.125–0.5 (0.24) | ||
|
| 09 (20.93 %) | AMB | 0.03–0.06 (0.03) |
| FLZ | 0.125–64 (7.77) | ||
| PO | 0.125–0.5 (0.87) | ||
|
| 02 (4.65 %) | AMB | 0.03–0.03 (0.03) |
| FLZ | 0.5–0.5 (0.5) | ||
| PO | 0.125–0.125 (0.12) | ||
|
| 07 (16.28 %) | AMB | 0.03–1.0 (0.24) |
| FLZ | 2.0–4.0 (2.85) | ||
| PO | 0.125–0.25 (0.18) | ||
|
| 02 (4.65 %) | AMB | 0.03–1.0 (0.51) |
| FLZ | 16–32 (24) | ||
| PO | 0.125–0.25 (0.19) |
Clinical and mycological evaluation of the antifungal activity of the piroctone olamine in experimental intra-abdominal candidiasis
| Control group versus treatment group | |||
|---|---|---|---|
| Rat/number | FG scoring | ||
| Liver | Spleen | Kidneys | |
|
| |||
| 1 | 1 | 0 | 1 |
| 2 | 1 | 1 | 1 |
| 3 | 1 | 0 | 1 |
| 4 | 1 | 1 | 0 |
| 5 | 1 | 1 | 0 |
| 6 | 1 | 0 | 0 |
|
| |||
| 1 | 0 | 1 | 0 |
| 2 | 0 | 1 | 0 |
| 3 | 0 | 0 | 0 |
| 4 | 1 | 0 | 0 |
| 5 | 1 | 0 | 0 |
| 6 | 1 | 0 | 0 |
|
| |||
| 1 | 0 | 0 | 0 |
| 2 | 1 | 0 | 0 |
| 3 | 0 | 0 | 0 |
| 4 | 1 | 1 | 0 |
| 5 | 0 | 0 | 0 |
| 6 | 1 | 0 | 0 |
PO piroctone olamine, AMB amphotericin B, FG fungal growth in culture media: (0) no fungal growth and (1) fungal growth